Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 2, 2012, Pages 183-190

  Kim, Y H ^a   Yang, T Y ^b   Park, C S ^c   Ahn, S H ^a   Son, B K ^a   Kim, J H ^a   Lim, D H ^a   Jang, T Y ^a  

^a Inha University School of Medicine   (South Korea)

^b CoA ENT Clinic ^*  (South Korea)

^c Departments of Pharmacology   (South Korea)

Author keywords

allergic rhinitis; allergy; atopy; interleukin 33

Indexed keywords

CYTOKINE ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 33 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; OVALBUMIN; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG LAVAGE; LYMPHOCYTE; MORPHOLOGY; MOUSE; NEUTROPHIL; NONHUMAN; NOSE CAVITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBODIES; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; FEMALE; IMMUNOGLOBULIN E; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-13; MICE; MICE, INBRED BALB C; OVALBUMIN; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84855765388     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02735.x     Document Type: Article

References (26)

1. Kurowska-Stolarska M, Hueber A, Stolarski B, McInnes IB,. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 2011; 269: 29-35.
2. Lloyd CM,. IL-33 family members and asthma-bridging innate and adaptive immune responses. Curr Opin Immunol 2010; 22: 800-806.
3. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, et al., Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 2001; 285: 1377-1383. (Pubitemid 32912936)
4. Moussion C, Ortega N, Girard JP,. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 2008; 3: e3331.
5. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al., IL-33 induces antigen-specific IL-5 + T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181: 4780-4790.
6. Kearley J, Buckland KF, Mathie SA, Lloyd CM,. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009; 179: 772-781.
7. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T,. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 2009; 386: 181-185.
8. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y,. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002; 32: 1520-1526. (Pubitemid 35278923)
9. Pushparaj PN, Tay HK, H'ng SC, Pitman N, Xu D, McKenzie A, et al., The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009; 106: 9773-9778.
10. Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, et al., Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999; 190: 895-902. (Pubitemid 29480818)
11. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al., Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008; 20: 791-800. (Pubitemid 351791523)
12. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al., Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992; 148: 2390-2394.
13. Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, et al., Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol 1993; 151: 3853-3865. (Pubitemid 23282697)
14. Saito H, Asakura K, Ogasawara H, Watanabe M, Kataura A,. Topical antigen provocation increases the number of immunoreactive IL-4-, IL-5- and IL-6-positive cells in the nasal mucosa of patients with perennial allergic rhinitis. Int Arch Allergy Immunol 1997; 114: 81-85. (Pubitemid 27338468)
15. Saito H, Matsumoto K, Denburg AE, Crawford L, Ellis R, Inman MD, et al., Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency. J Immunol 2002; 168: 3017-3023. (Pubitemid 34211683)
16. El Gazzar M, El Mezayen R, Marecki JC, Nicolls MR, Canastar A, Dreskin SC,. Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol 2006; 6: 1135-1142. (Pubitemid 43728167)
17. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA,. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009; 113: 1526-1534.
18. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490. (Pubitemid 41587888)
19. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H,. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008; 121: 1484-1490. (Pubitemid 351787349)
20. Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, et al., Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008; 88: 1245-1253.
21. Finkelman FD, Urban JF Jr,. The other side of the coin: the protective role of the TH2 cytokines. J Allergy Clin Immunol 2001; 107: 772-780. (Pubitemid 32436908)
22. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B,. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4 + T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091-1098.
23. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C,. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 1997; 99: 1492-1499. (Pubitemid 27163799)
24. Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA,. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol 1999; 162: 6233-6237. (Pubitemid 29314987)
25. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG,. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996; 183: 195-201. (Pubitemid 26028759)
26. Cocks BG, de Waal Malefyt R, Galizzi JP, de Vries JE, Aversa G,. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int Immunol 1993; 5: 657-663. (Pubitemid 23209420)